Ocular Therapeutix Reports Q4 CY2025 Revenue Miss, Down 22.4% YoY to $13.25 Million

Ocular Therapeutix (NASDAQ:OCUL) reported Q4 CY2025 revenue of $13.25 million, a 22.4% YoY decline and a 11% miss on estimates. Non-GAAP loss per share was $0.29, beating analyst expectations by 13.9%. The company's adjusted EBITDA declined 38.1% YoY to -$68.51 million, and free cash flow was -$57.09 million, compared to -$39.63 million in the same quarter last year. Market capitalization is $1.82 billion.